Doc Go Inc. DCGO
We take great care to ensure that the data presented and summarized in this overview for DocGo Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DCGO
View all-
Black Rock Inc. New York, NY7.04MShares$7.53 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$5.44 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.62MShares$4.95 Million0.12% of portfolio
-
P.A.W. Capital Corp3.2MShares$3.42 Million9.43% of portfolio
-
Knott David M Jr Syosset, NY3.07MShares$3.29 Million2.32% of portfolio
-
S Squared Technology, LLC New York, NY2.43MShares$2.6 Million1.36% of portfolio
-
Geode Capital Management, LLC Boston, MA2.19MShares$2.34 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.14MShares$2.29 Million0.01% of portfolio
-
State Street Corp Boston, MA1.93MShares$2.07 Million0.0% of portfolio
-
Moore Capital Management, LP New York, NY1.47MShares$1.57 Million0.03% of portfolio
Latest Institutional Activity in DCGO
Top Purchases
Top Sells
About DCGO
DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Insider Transactions at DCGO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
Lee Bienstock Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
214,131
-7.02%
|
$0
$0.91 P/Share
|
|
Dec 15
2025
|
Norman Rosenberg CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
65,774
-5.1%
|
$0
$0.91 P/Share
|
|
Dec 15
2025
|
Ely D Tendler General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
16,850
-6.11%
|
$0
$0.91 P/Share
|
|
Dec 15
2025
|
Stephen Sugrue Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,968
-5.35%
|
$0
$0.91 P/Share
|
|
Dec 12
2025
|
Lee Bienstock Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,113,495
+26.74%
|
-
|
|
Dec 12
2025
|
Norman Rosenberg CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
429,405
+24.98%
|
-
|
|
Dec 12
2025
|
Etalvina Leite Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.69%
|
-
|
|
Dec 12
2025
|
Michael J Burdiek Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+15.93%
|
-
|
|
Dec 12
2025
|
Ely D Tendler General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+26.62%
|
-
|
|
Dec 12
2025
|
Stephen Sugrue Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
321,055
+32.31%
|
-
|
|
Dec 12
2025
|
James M Travers Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+38.36%
|
-
|
|
Dec 12
2025
|
Ira Smedra Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+38.36%
|
-
|
|
Sep 10
2025
|
Stephen K. M.D. Klasko Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+46.51%
|
-
|
|
Jul 02
2025
|
Lee Bienstock Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,597
-0.95%
|
$18,597
$1.52 P/Share
|
|
Jul 02
2025
|
Norman Rosenberg CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,332
-1.3%
|
$11,332
$1.52 P/Share
|
|
Jul 02
2025
|
Stephen Sugrue Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,813
-1.63%
|
$5,813
$1.52 P/Share
|
|
May 23
2025
|
Michael J Burdiek Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.53%
|
$10,000
$1.33 P/Share
|
|
May 15
2025
|
Michael J Burdiek Director |
BUY
Open market or private purchase
|
Direct |
15,000
+2.32%
|
$15,000
$1.43 P/Share
|
|
May 14
2025
|
Norman Rosenberg CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
15,000
+1.69%
|
$15,000
$1.47 P/Share
|
|
May 14
2025
|
Stephen Sugrue Chief Compliance Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+2.72%
|
$10,000
$1.44 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.38M shares |
|---|---|
| Open market or private purchase | 80K shares |
| Payment of exercise price or tax liability | 501K shares |
|---|---|
| Open market or private sale | 16.9K shares |